AstraZeneca Plc – Product Pipeline Review

Global Markets Direct’s, ‘AstraZeneca Plc – Product Pipeline Review – 2016’, provides an overview of the AstraZeneca Plc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AstraZeneca Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of AstraZeneca Plc

The report provides overview of AstraZeneca Plc including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses AstraZeneca Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features AstraZeneca Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate AstraZeneca Plc’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for AstraZeneca Plc

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding AstraZeneca Plc’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

AstraZeneca Plc Snapshot 8

AstraZeneca Plc Overview 8

Key Information 8

Key Facts 8

AstraZeneca Plc - Research and Development Overview 9

Key Therapeutic Areas 9

AstraZeneca Plc - Pipeline Review 19

Pipeline Products by Stage of Development 19

Pipeline Products - Monotherapy 20

Pipeline Products - Combination Treatment Modalities 21

Pipeline Products - Partnered Products 22

Pipeline Products - Out-Licensed Products 25

AstraZeneca Plc - Pipeline Products Glance 27

AstraZeneca Plc - Late Stage Pipeline Products 27

AstraZeneca Plc - Clinical Stage Pipeline Products 30

AstraZeneca Plc - Early Stage Pipeline Products 34

AstraZeneca Plc - Drug Profiles 39

(avibactam + ceftazidime) 39

(dapagliflozin propanediol + saxagliptin) 41

(formoterol fumarate + glycopyrrolate) 43

(metformin hydrochloride + saxagliptin) 45

brodalumab 47

cangrelor tetrasodium 49

cediranib maleate 51

ceftaroline fosamil 54

dapagliflozin propanediol 57

osimertinib mesylate 60

propofol 63

ticagrelor 64

(aclidinium bromide + formoterol fumarate) 68

(budesonide + formoterol fumarate + glycopyrrolate) 70

(dapagliflozin propanediol + metformin hydrochloride + saxagliptin) 72

fulvestrant 74

gefitinib 76

glycopyrrolate 81

olaparib 83

omega-3-carboxylic acids 87

PT-009 89

quetiapine fumarate ER 90

roxadustat 91

selumetinib sulfate 94

AZD-3293 98

AZD-4547 99

(avibactam sodium + ceftaroline fosamil) 101

abediterol napadisylate 102

AZD-1775 104

AZD-1981 106

AZD-2014 107

AZD-3241 109

AZD-3759 110

AZD-4017 111

AZD-5363 113

AZD-7594 115

AZD-7624 116

AZD-9150 117

interferon beta-1a 118

lesogaberan 120

PT-008 121

RDEA-3170 122

sapitinib 123

saracatinib difumarate 125

savolitinib 127

Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease 130

AZD-5069 131

AZD-5312 133

(allopurinol + lesinurad) 134

(avibactam sodium + aztreonam lysine) 135

(insulin human + pramlintide acetate) 136

ARC-165395XX 137

AZD-0156 138

AZD-0424 139

AZD-3965 140

AZD-4076 142

AZD-5634 143

AZD-5718 144

AZD-6738 145

AZD-7451 147

AZD-7986 148

AZD-8108 149

AZD-8186 150

AZD-8835 151

AZD-8871 152

AZD-8999 153

AZD-9496 154

AZD-9567 155

dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide 156

LAS-40468 157

MEDI-7352 158

AC-163794 159

ADP-31417 160

ADP-71296 161

AZ-12260493 162

AZ-12441970 163

AZ-12861903 164

AZ-13483342 165

AZ-20 166

AZ-4217 167

AZ-4425 168

AZ-64 169

AZ-709 170

AZ-876 171

AZD-0449 172

AZD-2098 173

AZD-2858 174

AZD-3463 175

AZD-3857 176

AZD-4831 177

AZD-9708 178

CWGNC-41 179

Drug 1 for Cancer 180

Drug 2 for Cancer 181

Drug 3 for Cancer 182

Drug 4 for Cancer 183

Drug 5 for Cancer 184

Drug 6 for Cancer 185

HTL-1071 186

KU-59403 187

LAS-191351 188

LAS-194871 189

LCB-010200 190

MMV-253 191

Monoclonal Antibody Conjugates for Oncology 192

NBTI-5463 193

NKTR-119 194

OX-CLI 195

PL-8905 196

Small Molecule for Malaria 197

Small Molecule for Oncology 198

Small Molecule to Antagonize Histamine 3 Receptor for Cognition 199

Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology 200

Small Molecule to Block Kv1.5 for Atrial Fibrillation 201

Small Molecule to Inhibit DNA Gyrase for Streptococcal Pneumonia 202

Small Molecule to Inhibit PI3K Beta for Bleeding and Clotting Disorders 203

Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia 204

Small Molecules 1 for Malaria 205

Small Molecules for Dyslipidemia and Hypertriglyceridemia 206

Small Molecules to Antagonize GPR103 for Obesity 207

Small Molecules to Antagonize M3 Receptors for Respiratory Disorders 208

Small Molecules to Antagonize P2X3 for Chronic Pain 209

Small Molecules to Inhibit CDK9 for Inflammatory Pain and Rheumatoid Arthritis 210

Small Molecules to Inhibit DNA GyrB for Tuberculosis 211

Small Molecules to Inhibit DprE1 for Tuberculosis 212

Synthetic Peptide for Neuropathic Pain 213

VU-0467154 214

AZ-0108 215

AZ-12201182 216

AZ-27 217

AZ-465 218

AZ-6142 219

AZ-82 220

AZD-3147 221

Drugs for Cardiovascular Diseases 222

HD-001 223

Small Molecule 1 for Malaria 224

Small Molecule to Inhibit 11beta-HSD-1 for Type 2 Diabetes 225

Small Molecule to Inhibit Src Tyrosine Kinase for Lymphangioleiomyomatosis 226

Small Molecules for Diabetic Nephropathy 227

Small Molecules for Tuberculosis 228

Small Molecules to Inhibit Acetohydroxyacid Synthase for Mycobacterium Infections 229

Small Molecules to Inhibit ATP Synthesis for Tuberculosis 230

Small Molecules to Inhibit Carboxypeptidase U for Thrombosis 231

Small Molecules to Inhibit DNA Gyrase B for Tuberculosis 232

Small Molecules to Inhibit DXP-Reductoisomerase for Malaria 233

Small Molecules to Inhibit MALT-1 for Oncology and Autoimmune Disorders 234

Small Molecules to Inhibit p38alpha MAP Kinase for Inflammatory Diseases 235

Small Molecules to Inhibit PLA2 for Undisclosed Indication 236

AstraZeneca Plc - Pipeline Analysis 237

AstraZeneca Plc - Pipeline Products by Target 237

AstraZeneca Plc - Pipeline Products by Route of Administration 246

AstraZeneca Plc - Pipeline Products by Molecule Type 247

AstraZeneca Plc - Pipeline Products by Mechanism of Action 248

AstraZeneca Plc - Recent Pipeline Updates 254

AstraZeneca Plc - Dormant Projects 316

AstraZeneca Plc - Discontinued Pipeline Products 319

Discontinued Pipeline Product Profiles 324

AstraZeneca Plc - Company Statement 344

AstraZeneca Plc - Locations And Subsidiaries 348

Head Office 348

Other Locations & Subsidiaries 348

AstraZeneca Plc - Key Manufacturing Facilities 353

Appendix 354

Methodology 354

Coverage 354

Secondary Research 354

Primary Research 354

Expert Panel Validation 354

Contact Us 354

Disclaimer 355

List of Tables

List of Tables

AstraZeneca Plc, Key Information 22

AstraZeneca Plc, Key Facts 22

AstraZeneca Plc – Pipeline by Indication, 2016 24

AstraZeneca Plc – Pipeline by Stage of Development, 2016 33

AstraZeneca Plc – Monotherapy Products in Pipeline, 2016 34

AstraZeneca Plc – Combination Treatment Modalities in Pipeline, 2016 35

AstraZeneca Plc – Partnered Products in Pipeline, 2016 36

AstraZeneca Plc – Partnered Products/ Combination Treatment Modalities, 2016 37

AstraZeneca Plc – Out-Licensed Products in Pipeline, 2016 39

AstraZeneca Plc – Out-Licensed Products/ Combination Treatment Modalities, 2016 40

AstraZeneca Plc – Pre-Registration, 2016 41

AstraZeneca Plc – Filing rejected/Withdrawn, 2016 42

AstraZeneca Plc – Phase III, 2016 43

AstraZeneca Plc – Phase II, 2016 44

AstraZeneca Plc – Phase I, 2016 46

AstraZeneca Plc – Preclinical, 2016 48

AstraZeneca Plc – Discovery, 2016 51

AstraZeneca Plc – Pipeline by Target, 2016 251

AstraZeneca Plc – Pipeline by Route of Administration, 2016 260

AstraZeneca Plc – Pipeline by Molecule Type, 2016 261

AstraZeneca Plc – Pipeline Products by Mechanism of Action, 2016 262

AstraZeneca Plc – Recent Pipeline Updates, 2016 268

AstraZeneca Plc – Dormant Developmental Projects,2016 330

AstraZeneca Plc – Discontinued Pipeline Products, 2016 333

AstraZeneca Plc, Subsidiaries 362

AstraZeneca Plc, Key Manufacturing Facilities 367

List of Figures

List of Figures

AstraZeneca Plc – Pipeline by Top 10 Indication, 2016 24

AstraZeneca Plc – Pipeline by Stage of Development, 2016 33

AstraZeneca Plc – Monotherapy Products in Pipeline, 2016 34

AstraZeneca Plc – Combination Treatment Modalities in Pipeline, 2016 35

AstraZeneca Plc – Partnered Products in Pipeline, 2016 36

AstraZeneca Plc – Out-Licensed Products in Pipeline, 2016 39

AstraZeneca Plc – Pipeline by Top 10 Target, 2016 251

AstraZeneca Plc – Pipeline by Route of Administration, 2016 260

AstraZeneca Plc – Pipeline by Molecule Type, 2016 261

AstraZeneca Plc – Pipeline Products by Top 10 Mechanism of Action, 2016 262

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports